Seragon Biosciences published preclinical results in Drug Design, Development and Therapy for SRN-901, an oral combinatorial longevity drug, reporting coordinated multi-omics changes and physiological benefits in aged mice.
SRN-901-treated 18-month-old C57BL/6 mice fed a Western diet showed a 33% increase in median remaining lifespan versus placebo. The company claims a Cox proportional hazards analysis found a 46% reduction in the hazard of death, and notes that benchmark rapamycin increased median lifespan by 21% while NMN and NR did not show significant lifespan differences.
Seragon reports a 70% attenuation of frailty progression relative to controls and a 30.53% reduction in tumor incidence in treated animals. Multi-omics profiling is described as showing upregulation of DNA repair and pathways tied to cellular repair, energy metabolism and stress resistance, with downregulation of apoptosis, inflammatory response, reactive oxygen species and mTORC1 signaling.
The study treated mice until death with SRN-901 at 500 mg/kg/day by oral gavage and included placebo and comparator arms; the company positions SRN-901 as a multi-target intervention combining longevity-associated compounds with its SRN-820.
